We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+8.67%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.15B
AUM Growth
-$198M
Cap. Flow
-$346M
Cap. Flow %
-10.98%
Top 10 Hldgs %
41.12%
Holding
79
New
11
Increased
20
Reduced
24
Closed
8

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$70.4M
2
MBX
MBX Biosciences
MBX
+$69M
3
IMVT icon
Immunovant
IMVT
+$43.2M
4
ORKA
Oruka Therapeutics
ORKA
+$43M
5
GH icon
Guardant Health
GH
+$42.5M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$180M
2
INSM icon
Insmed
INSM
+$134M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$122M
4
AXSM icon
Axsome Therapeutics
AXSM
+$86.9M
5
TVTX icon
Travere Therapeutics
TVTX
+$71.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.35%
2 Miscellaneous 0.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
26
Abivax
ABVX
$9.05B
$41.2M 1.31%
3,579,209
-600,554
-14% -$7.2M
TGTX icon
27
TG Therapeutics
TGTX
$8.46B
$40.3M 1.28%
1,725,000
-1,145,131
-40% -$25M
DFTX
28
Definium Therapeutics
DFTX
$5.11B
$40.2M 1.28%
7,065,099
+961,282
+16% +$6.69M
KURA icon
29
Kura Oncology
KURA
$1B
$38.4M 1.22%
1,963,505
+1,578,749
+410% +$32M
GERN icon
30
Geron
GERN
$829M
$34.4M 1.09%
7,575,049
-5,424,951
-42% -$24.7M
CYTK icon
31
Cytokinetics
CYTK
$9.74B
$33.3M 1.05%
629,906
+497,411
+375% +$27.7M
ORKA
32
Oruka Therapeutics
ORKA
$6.23B
$30.3M 0.96%
+1,235,187
New +$43M
ANIP icon
33
ANI Pharmaceuticals
ANIP
$1.69B
$30.1M 0.96%
504,828
+38,739
+8% +$2.36M
SYRE icon
34
Spyre Therapeutics
SYRE
$8.03B
$29.4M 0.93%
1,000,000
-756,667
-43% -$21.1M
EWTX icon
35
Edgewise Therapeutics
EWTX
$4.85B
$29.4M 0.93%
1,100,536
+914,150
+490% +$18.2M
KYMR icon
36
Kymera Therapeutics
KYMR
$9.66B
$28.4M 0.9%
600,326
-899,674
-60% -$39.7M
KRRO icon
37
Korro Bio
KRRO
$213M
$28.4M 0.9%
850,000
+79,355
+10% +$3.34M
RNAM
38
DELISTED
Avidity Biosciences
RNAM
$21.8M 0.69%
+475,000
New +$20.6M
CNTA
39
DELISTED
Centessa Pharmaceuticals
CNTA
$21.6M 0.68%
+1,350,000
New +$16.5M
ALEC icon
40
Alector
ALEC
$222M
$21.6M 0.68%
4,631,998
– –
NKTR icon
41
Nektar Therapeutics
NKTR
$2.26B
$20.7M 0.66%
1,061,510
-130,190
-11% -$2.48M
ETNB
42
DELISTED
89bio
ETNB
$20.5M 0.65%
2,766,512
+472,501
+21% +$3.97M
BCAX
43
Bicara Therapeutics
BCAX
$1.48B
$20.3M 0.64%
+796,852
New +$20.3M
AKRO
44
DELISTED
Akero Therapeutics
AKRO
$19.8M 0.63%
+689,784
New +$18M
FATE icon
45
Fate Therapeutics
FATE
$288M
$19.5M 0.62%
5,572,607
– –
SLN
46
Silence Therapeutics
SLN
$768M
$18.2M 0.58%
1,000,000
-359,745
-26% -$6.69M
AXSM icon
47
CALL
Axsome Therapeutics
AXSM
$11.1B
$18M 0.57%
+200,000
New +$17.5M
ENGN icon
48
enGene Therapeutics
ENGN
$127M
$17.2M 0.55%
2,607,633
+357,633
+16% +$2.66M
EDIT icon
49
Editas Medicine
EDIT
$416M
$16.7M 0.53%
4,900,334
-1,099,666
-18% -$4.79M
XNCR icon
50
Xencor
XNCR
$1.78B
$16.1M 0.51%
+800,000
New +$15M
1
2
3 4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Deep Track Capital held 79 positions worth $3.15B, down 5.9% from $3.35B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Deep Track Capital withdrew a net $346M in Q3 2024, closing 8 positions and reducing 24 holdings. Its most notable exit was Amgen, an estimated $180M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Deep Track Capital opened a new position in MBX Biosciences worth $78.4M.

  • Deep Track Capital's largest Q3 2024 buy was MBX Biosciences: 3,018,935 shares worth $78.4M.
  • Deep Track Capital added most to Apellis Pharmaceuticals in Q3 2024, an estimated $70.4M increase.
  • Deep Track Capital's biggest Q3 2024 reduction was Axsome Therapeutics, cutting an estimated $86.9M.
  • Deep Track Capital fully exited Amgen in Q3 2024, selling an estimated $180M.
  • Deep Track Capital's ten largest holdings make up 41% of its $3.15B portfolio in Q3 2024.
  • Deep Track Capital opened 11 new positions and closed 8 in Q3 2024.
  • Deep Track Capital's portfolio value fell 5.9% quarter-over-quarter to $3.15B.

Based on Deep Track Capital's 13F filing for Q3 2024, filed 14 Nov 2024.